Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.55 |
| ▸ | PLAU | P00749 | 3/20 | 0.47 |
| ▸ | PLG | P00747 | 2/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 3/20 | 0.41 |
| ▸ | CCND1 | P24385 | 3/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789563 | 0.84 | PRKCI (0.56) | PRKCIPLAUPLGNTSR1EGFR | |
| SCHEMBL30672832 | 0.82 | PRKCI (0.55) | PRKCIPLAUPLGNTSR1EGFR | |
| SCHEMBL3650822 | 0.82 | PRKCI (0.59) | PRKCIPLAUPLGNTSR1EGFR | |
| SCHEMBL16370787 | 0.82 | PRKCI (0.55) | PRKCIPLAUPLGNTSR1EGFR | |
| SCHEMBL24669590 | 0.79 | PLG (0.45) | PLAUPLGCDK4CCND1ACACB | |
| SCHEMBL5089820 | 0.79 | PRKCI (0.56) | PRKCIPLAUPLGNTSR1KDM4E | |
| SCHEMBL31561786 | 0.79 | HTR2C (0.55) | PLAUPLGCDK4CCND1ACACB | |
| SCHEMBL25310410 | 0.79 | HTR2C (0.55) | PLAUPLGCDK4CCND1ACACB | |
| SCHEMBL256348 | 0.79 | PLG (0.44) | PLAUPLGCDK4CCND1ACACB | |
| SCHEMBL11622820 | 0.79 | HTR2A (0.57) | PLAUPLGKDM4ECDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9622991-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2017-04-18 | — | — | US | disclosed |
| CN-102656141-B | Micromolecular compound of simulation hemopoieticgrowth factor and uses thereof | LIGAND PHARMACEUTICALS INC. (US) | 2016-04-06 | — | — | CN | disclosed |
| US-9144557-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-09-10 | — | — | US | disclosed |
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | HGF, EPOR, MPL | PRKCI 2155/4885PLAU 1083/4885PLG 1274/4885 |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | PRKCI 2706/4885PLAU 1830/4885PLG 1732/4885 |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | PRKCI 2706/4885PLAU 1830/4885PLG 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.